Interim Management Statement

Interim Management Statement Introduction I am pleased to present the Company's interim management statement for the period from 1 April 2010 to 26 July 2010 as required by the UK Listing Authority's Disclosure and Transparency Rule 4.3. Performance and dividends The Company's unaudited net asset value (NAV) as at 30 June 2010 was £26.3 million (31 March 2010: £26.8 million) or 86.8 pence per share (31 March 2010: 88.3 pence per share). The net asset value for 30 June 2010 is after accounting for the first dividend for the year to 31 March 2011 of 1.5 pence per share (total cost: £454,000), to be paid 6 August 2010 to shareholders on the register as at 9 July 2010. The net asset value remains broadly the same as the net asset value at 31 March 2010. Encouragingly, revenue return has increased due to the increased rate of investment. The Board is not aware of any significant events or transactions between 30 June 2010 and the date of this interim management statement which would have a material impact on the net asset value of the Company. Share buybacks During the period from 1 April 2010 to 26 July 2010, the Company purchased 22,544 shares at an average price of 75 pence per share, to be held in treasury. The current share price is 75 pence. Portfolio Further investments have been made during the period from 1 April 2010 to 26 July 2010: +-----------------------------------+------+-----------------------------------+ |Name |£000's|   | +-----------------------------------+------+-----------------------------------+ |Masters Pharmaceuticals Limited |980 |International specialist | | | |distribution of pharmaceuticals | +-----------------------------------+------+-----------------------------------+ |BBVA Senior Finance floating rate |3,000 |Floating rate note | |note: maturity date 8 November 2011| | | +-----------------------------------+------+-----------------------------------+ Disposals There were no disposals during the period from 1 April 2010 to 26 July 2010. Top ten holdings (as at 26 July 2010) +---------------------------------------------------------------------+------+ |Investment |Value | | |£000's| +---------------------------------------------------------------------+------+ |BBVA Senior Finance floating rate note: maturity date 8 November 2011|3,000 | +---------------------------------------------------------------------+------+ |UBS floating rate note: maturity date 20 May 2011 |2,525 | +---------------------------------------------------------------------+------+ |Geronimo Inns I VCT Limited |1,589 | +---------------------------------------------------------------------+------+ |Geronimo Inns II VCT Limited |1,589 | +---------------------------------------------------------------------+------+ |Bravo Inns II Limited |1,393 | +---------------------------------------------------------------------+------+ |Taunton Nursing Home Limited |1,014 | +---------------------------------------------------------------------+------+ |Prime Care Holdings Limited |991 | +---------------------------------------------------------------------+------+ |Masters Pharmaceuticals Limited |985 | +---------------------------------------------------------------------+------+ |Forth Photonics Limited |925 | +---------------------------------------------------------------------+------+ |Mi-Pay Limited |808 | +---------------------------------------------------------------------+------+ Further information regarding historic and current financial performance and other useful shareholder information can be found on the Fund's website underwww.albion-ventures.co.uk/Our Funds/Albion Enterprise VCT PLC. Maxwell Packe, Chairman 26 July 2010 For further information please contact: Patrick Reeve, Albion Ventures LLP - tel: 020 7601 1850 [HUG#1434010] This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Albion Enterprise VCT PLC via Thomson Reuters ONE
UK 100